Last reviewed · How we verify
Soliris
At a glance
| Generic name | Soliris |
|---|---|
| Also known as | Eculizumab, eculizumab |
| Sponsor | Apellis Pharmaceuticals, Inc. |
| Target | Complement C5 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Atypical hemolytic uremic syndrome
- Congenital hemolytic uremic syndrome
- Neuromyelitis optica
- Paroxysmal nocturnal hemoglobinuria
- Refractory generalized myasthenia gravis
Common side effects
- Headache
- Nasopharyngitis
- Back pain
- Nausea
- Diarrhea
- Hypertension
- Upper respiratory infection
- Abdominal pain
- Vomiting
- Anemia
- Cough
- Peripheral edema
Serious adverse events
- Meningococcal sepsis
- Meningococcal meningitis
- Viral infection
- Headache
- Anemia
- Pyrexia
- Infection
- Progression of PNH
- Thrombotic event
Key clinical trials
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works (PHASE3)
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD (PHASE4)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)
- Danicopan Early Access Program
- A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment (PHASE3)
- Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (PHASE4)
- Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Soliris CI brief — competitive landscape report
- Soliris updates RSS · CI watch RSS
- Apellis Pharmaceuticals, Inc. portfolio CI